Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 8Other solid neoplasm 2NET 2Head & Neck 2Classical hematology 2CNS 2Myeloid 1

Conditions

Neuroendocrine Tumors 531Gastro-enteropancreatic neuroendocrine tumor 58Carcinoid Tumor 58Neoplasms 49Carcinoma, Neuroendocrine 44Pancreatic Neoplasms 36Adenoma, Islet Cell 33Neoplasm Metastasis 28Pheochromocytoma 25Colorectal Neoplasms 24Paraganglioma 23Stomach Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Lung Neoplasms 20Carcinoma, Hepatocellular 20Sarcoma 19Carcinoma 19Thyroid Neoplasms 18Gastrointestinal Neoplasms 18Neuroblastoma 15Cholangiocarcinoma 14Carcinoma, Renal Cell 14Small Cell Lung Carcinoma 13Melanoma 13Esophageal Neoplasms 13Serotonin Syndrome 12Colonic Neoplasms 12Brain Neoplasms 11Adenocarcinoma 11

Interventions

fluorodopa F 18 2Furosemide 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Congenital Hyperinsulinism × NET × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT03042416 2022-01-10

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

University of Alberta

Phase 3 Completed
400 enrolled
CNSEndocrineNET

Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡